Big Pharma Breaks the Bank in Late-Stage Licensing
Executive Summary
2006 saw an order of magnitude jump in up-front payments in late clinical licensing deals over previous years, and the trend looks to continue in 2007.
You may also be interested in...
The Value of Proof-Of-Concept
Big Pharma's unprecedented spending levels in licensing continue. But some recent deals suggest the real linchpin of licensing value is proof-of-concept in humans.
The Value of Proof-Of-Concept
Big Pharma's unprecedented spending levels in licensing continue. But some recent deals suggest the real linchpin of licensing value is proof-of-concept in humans.
Deal Statistics Quarterly, Q1 2007
We present another installment of our quarterly review of dealmaking-for January-March 2007. Our data comes from Windhover's Strategic Transactions Database, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics and research industries.